NYSE: BSX
Boston Scientific Corporation
Healthcare · Medical - Devices
After hours: $46.85(+0.02%) · as of 7:59 PM ET
Market Cap
$69.62B
52w High
$109.50
52w Low
$42.20
P/E
18.97
Volume
17.14M
Outstanding Shares
1.49B
Valuation Data Insufficient
The DCF model's fair value estimate is more than 3× the current stock price. This typically indicates unreliable model inputs — such as irregular cash flows or balance sheet distortions — rather than a genuine opportunity, so the valuation is not shown.
Performance
Return analysis
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 55.71% over the last year. Revenue grew 13.53% over the trailing twelve months. Operating margin moved from 16.1% to 21.46%. Free cash flow grew 9.48% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price, and the shares now sit around the 3rd percentile of their historical P/FCF range. That looks more like a rerating of the multiple than a collapse in the business.
What would invalidate this read
This read changes if operating margin (currently 21.46%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe.
Valuation
Stock splits
Every 1 shares became 2
Every 1 shares became 2
Profitability & growth
Analyst consensus
38
Buy
6
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Oct 28, 2026
Q4 FY26 · EPS est $0.80 · Revenue est $5.26B
View